News
ADAG
1.780
-3.78%
-0.070
Weekly Report: what happened at ADAG last week (1215-1219)?
Weekly Report · 5d ago
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
NASDAQ · 12/17 13:43
Adagene, Palvella gain after FDA Fast Track Designations
Seeking Alpha · 12/16 14:24
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Novan (NOVN) and Adagene (ADAG)
TipRanks · 12/16 13:20
Why Adagene Is Rising In Pre-market?
NASDAQ · 12/16 12:30
Adagene announces FDA fast track designation for muzastotug
TipRanks · 12/16 12:05
Weekly Report: what happened at ADAG last week (1208-1212)?
Weekly Report · 12/15 10:20
Weekly Report: what happened at ADAG last week (1201-1205)?
Weekly Report · 12/08 10:19
Weekly Report: what happened at ADAG last week (1124-1128)?
Weekly Report · 12/01 10:14
Adagene Price Target Announced at $9.00/Share by Guggenheim
Dow Jones · 11/24 13:40
Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Benzinga · 11/24 13:30
Adagene initiated with a Buy at Guggenheim on muzastotug potential
TipRanks · 11/24 13:10
Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Adagene (ADAG)
TipRanks · 11/24 13:10
Adagene initiated with a Buy at Guggenheim
TipRanks · 11/24 11:41
Weekly Report: what happened at ADAG last week (1117-1121)?
Weekly Report · 11/24 10:19
Weekly Report: what happened at ADAG last week (1110-1114)?
Weekly Report · 11/17 10:19
Adagene (ADAG) Gets a Buy from LifeSci Capital
TipRanks · 11/14 11:36
Adagene initiated with an Outperform at LifeSci Capital
TipRanks · 11/14 11:26
Adagene announces licensing agreement with Third Arc Bio
TipRanks · 11/13 12:31
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/11 17:09
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.